Recent advancements in gut microbiome research have highlighted the complex interplay between gut microbiota and various physiological and pathological processes, showing that gut microbiota plays a vital role in human health and disease. Imbalances in the gut microbiota, known as dysbiosis, have been associated with a range of health conditions, including gastrointestinal disorders, metabolic diseases, etc. In response to these findings, probiotics, prebiotics, synbiotics, and postbiotics have emerged as a promising therapeutic strategy to modulate gut microbiota composition and functionality. This review paper explores the latest research on how gut microbiota impacts host physiology, immune responses, and overall well-being. Furthermore, the paper delves into the therapeutic potential of probiotics, postbiotics, prebiotics, and synbiotics in therapeutic applications and curing various diseases. The paper also addresses the challenges and opportunities in the field, highlighting the need for personalized approaches to probiotic therapy and the importance of considering factors such as strain specificity, dosing, and safety.Overall, this review aims to provide a comprehensive overview of the evolving landscape of gut microbiota and probiotics, prebiotics, synbiotics, and postbiotics as novel therapeutic agents. It underscores the potential of harnessing the gut microbiome to improve health, prevent diseases, and complement traditional medical interventions. As research in this field continues to expand, a deeper understanding of the gut microbiota and probiotics, prebiotics, synbiotics, and postbiotics promises new avenues for preventive and therapeutic healthcare strategies.

Background: Probiotics have been found to be beneficial for human beings through the modulation of intestinal bacteria and inhibition of pathogens. In light of the increased prevalence of multidrug resistant uropathogens, there is a need for alternative therapies than antibiotics. Objectives: This study assessed the capacity of three probiotics (Lactobacillus acidophilus, Lactic Acid Bacillus and Probiotic Consortium) to inhibit three important uropathogens; Escherichia coli, Klebsiella and Staphylococcus aureus with a view of understanding their antibacterial mechanism of action. Methods: In vitro co-cultures were set up to monitor the growth of the pathogens, the development of biofilms and acidification of the culture media for 24 hours. Biofilm biomass inhibition was assessed using crystal violet microtiter plate assays. The molecular responses to probiotics of Escherichia coli was also assessed by analysis of transcriptomics of cell envelope stress genes (omp) and molecular chaperones (dnaK, chap). Results: The efficacy of biofilm inhibition was highly strain-dependent, such that Lactobacillus acidophilus always showed significantly greater broad spectrum biofilm inhibition than both the probiotic consortium and Lactic Acid Bacillus. Escherichia coli Biofilm Inhibition: L. acidophilus gave the highest inhibition of 66.67%, whereas the probiotic consortium inhibited 59.05% of the biofilms and Lactic Acid Bacillus 3.81%. Klebsiella Biofilm Inhibition: The best biofilm inhibition was observed with L. acidophilus with 78.00% compared to the probiotic consortium (61.11%) and Lactic Acid Bacillus (42.50%). Staphylococcus aureus Biofilm Inhibition: L. acidophilus showed maximal biofilm inhibition of 69.09% compared to 54.55% inhibition from the probiotic consortium. Inhibition showed high correlation with medium acidification and antimicrobial metabolite production. Transcriptome analysis: treatment with L. acidophilus caused severe cell envelope stress in E. coli (5.4-fold increase in expression of omp) and impaired intracellular stress response in E. coli with the inhibition of molecular chaperone (dnaK -4.0-fold and chap -2.6-fold. Conclusion: Lactobacillus acidophilus is a strong broad spectrum antibiofilm agent that targets Gram-negative and Gram-positive uropathogens. Antimicrobial activity of this bacterium is exerted through acidification, metabolite production, cell envelope stress induction, and regulation of stress response mechanisms.